LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 6 of 15: Mean cell count and mean growth rate across biological replicate 3. - Dataset (ID:20242)
Download: Excel (XLSX), Comma-separated (CSV)
Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Timepoint | Timepoint Unit | Mean Total Cell Count Before Treatment | Mean Total Cell Count After Treatment | Mean Total Control Cell Count | Mean Relative Cell Count | Mean Relative Growth Rate After Treatment |
---|---|---|---|---|---|---|---|---|---|---|---|
MDA-MB-231 | WZ-4-145 | 0.12 | uM | LJP6 | 72 | hr | 1235 | 3493 | 4513 | 0.7740 | 0.6887 |
MDA-MB-231 | XMD16-144 | 0.12 | uM | LJP5 | 72 | hr | 1235 | 1357 | 4513 | 0.3008 | 0.0371 |
MDA-MB-231 | Brivanib | 0.12 | uM | LJP5 | 72 | hr | 1235 | 4196 | 4513 | 0.9297 | 0.9032 |
MDA-MB-231 | Buparlisib | 0.12 | uM | LJP5 | 72 | hr | 1235 | 4457 | 4513 | 0.9875 | 0.9828 |
MDA-MB-231 | BX-912 | 0.12 | uM | LJP5 | 72 | hr | 1235 | 3850 | 4513 | 0.8530 | 0.7975 |
MDA-MB-231 | Canertinib | 0.12 | uM | LJP6 | 72 | hr | 1235 | 4322 | 4513 | 0.9577 | 0.9417 |
MDA-MB-231 | Celastrol | 0.12 | uM | LJP6 | 72 | hr | 1235 | 4729 | 4513 | 1.0477 | 1.0657 |
MDA-MB-231 | CGP60474 | 0.12 | uM | LJP5 | 72 | hr | 1235 | 773 | 4513 | 0.1713 | -0.1411 |
MDA-MB-231 | CGP60474 | 0.12 | uM | LJP6 | 72 | hr | 1235 | 506 | 4513 | 0.1121 | -0.2227 |
MDA-MB-231 | CHIR-99021 | 0.12 | uM | LJP6 | 72 | hr | 1235 | 3769 | 4513 | 0.8351 | 0.7729 |
MDA-MB-231 | CP724714 | 0.12 | uM | LJP5 | 72 | hr | 1235 | 4689 | 4513 | 1.0390 | 1.0537 |
MDA-MB-231 | CP466722 | 0.12 | uM | LJP5 | 72 | hr | 1235 | 4537 | 4513 | 1.0052 | 1.0071 |
MDA-MB-231 | Crizotinib | 0.12 | uM | LJP5 | 72 | hr | 1235 | 4475 | 4513 | 0.9915 | 0.9883 |
MDA-MB-231 | Momelotinib | 0.12 | uM | LJP5 | 72 | hr | 1235 | 3565 | 4513 | 0.7900 | 0.7108 |
MDA-MB-231 | Dasatinib | 0.12 | uM | LJP5 | 72 | hr | 1235 | 1345 | 4513 | 0.2981 | 0.0335 |
MDA-MB-231 | Dasatinib | 0.12 | uM | LJP6 | 72 | hr | 1235 | 801 | 4513 | 0.1775 | -0.1326 |
MDA-MB-231 | Dovitinib | 0.12 | uM | LJP5 | 72 | hr | 1235 | 3912 | 4513 | 0.8668 | 0.8166 |
MDA-MB-231 | Enzastaurin | 0.12 | uM | LJP5 | 72 | hr | 1235 | 4878 | 4513 | 1.0808 | 1.1113 |
MDA-MB-231 | Erlotinib | 0.12 | uM | LJP5 | 72 | hr | 1235 | 4277 | 4513 | 0.9476 | 0.9278 |
MDA-MB-231 | Foretinib | 0.12 | uM | LJP5 | 72 | hr | 1235 | 3081 | 4513 | 0.6828 | 0.5631 |
MDA-MB-231 | R406 | 0.12 | uM | LJP6 | 72 | hr | 1235 | 4308 | 4513 | 0.9544 | 0.9373 |
MDA-MB-231 | Pictilisib | 0.12 | uM | LJP6 | 72 | hr | 1235 | 3713 | 4513 | 0.8228 | 0.7559 |
MDA-MB-231 | Gefitinib | 0.12 | uM | LJP6 | 72 | hr | 1235 | 4265 | 4513 | 0.9450 | 0.9242 |
MDA-MB-231 | Geldanamycin | 0.12 | uM | LJP5 | 72 | hr | 1235 | 1210 | 4513 | 0.2681 | -0.0079 |
MDA-MB-231 | Geldanamycin | 0.12 | uM | LJP6 | 72 | hr | 1235 | 1101 | 4513 | 0.2439 | -0.0412 |